Pharmacotherapy for pneumococcal infections: An update

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 1, 2013, Pages 65-77

  Esposito, Susanna ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antimicrobial resistance; Antimicrobial therapy; Children; Pneumococcal infection; Pneumococcal vaccination; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFACLOR; CEFADROXIL; CEFOTAXIME; CEFPODOXIME PROXETIL; CEFTAROLINE; CEFTOBIPROLE; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN; CETHROMYCIN; CHLORAMPHENICOL; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; PENICILLIN DERIVATIVE; PENICILLIN G; PNEUMOCOCCUS VACCINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERIUM ISOLATE; CEREBROSPINAL FLUID; COMMUNITY ACQUIRED PNEUMONIA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION RISK; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIA; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; REVIEW; SEPSIS; SEROTYPE; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; DRUG RESISTANCE, MICROBIAL; HUMANS; MENINGITIS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEPSIS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84871580537     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.756867     Document Type: Review

References (96)

1. Andrade AL, Toscano CM, Minamisava R, et al. Pneumococcal disease manifestation in children before and after vaccination: what is new? Vaccine 2011;29(Suppl 3):C2-14
2. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009;30:89-209
3. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374:893-902
4. Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002;51:98-104 (Pubitemid 34136743)
5. Brugger SD, Hathaway LJ, Muhlemann K. Streptococcus pneumoniae strain co-colonization in the nasopharynx. J Clin Microbiol 2009;47:1750-6
6. Ward J. Antibiotic-resistant Streptococcus pneumoniae: clinical and epidemiologic aspects. Rev Infect Dis 1981;3:254-66
7. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9 (Pubitemid 32466340)
8. Riedel S, Beekmann SE, Heilmann KP, et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007;26:485-90 (Pubitemid 47025039)
9. Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Continued control of pneumococcal disease in the UK-the impact of vaccination. J Med Microbiol 2011;60(Pt 1):1-8
10. Tan TQ. Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA. Expert Rev Anti Infect Ther 2010;8:117-25
11. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009;15(Suppl 3):16-20
12. Cohen R, Levy C, Bonnet E, et al. Dynamics of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2010;28:6114-21
13. Aguiar SI, Serrano I, Pinto FR, et al. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008;14:835-43
14. Vestrheim DF, Høiby EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine 2010;28:2214-21
15. Harboe ZB, Benfield TL, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010;50:329-37
16. Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010;16:402-10
17. Brueggemann AB, Doern GV. Resistance among Streptococcus pneumoniae: patterns, mechanisms, interpreting the breakpoints. Am J Manag Care 2000;6(23 Suppl):S1189-96 (Pubitemid 32043644)
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. CLSI; Wayne, PA: 2010
19. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010;36:197-204
20. European Committee on Antimicrobial Susceptibility Testing. EUCAST. 2012.Available from: http://www.eucast. org/clinical-breakpoints/[Accessed 19 September 2012]
21. Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ASNORP study). Antimicrob Agents Chemother 2004;48:2101-210
22. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006;56:69-74 (Pubitemid 44279930)
23. Cornick JE, Bentley SD. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microb Infect 2012;14:573-83
24. Lauderdale TL, Wagener MM, Lin HM, et al. Serotype and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from Taiwanese children: comparison of nasopharyngeal and clinical isolates. Diagn Microbiol Infect Dis 2006;56:421-6 (Pubitemid 44854350)
25. Zhou L, Yu SJ, Gao W, et al. Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010. Vaccine 2011;29:7704-10
26. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int J Antimicrob Agents 2005;26:479-85 (Pubitemid 41635498)
27. Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin Infect Dis 2004;38(Suppl 4):S322-7 (Pubitemid 38669887)
28. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007;26:123-8 (Pubitemid 46183361)
29. Ishimine P. Fever without source in children 0 to 36 months of age. Pediatr Clin North Am 2006;53:167-94
30. Lagos RM, Munoz AE, Levine MM. Prevalence of pneumococcal bacteremia among children 36 months of age presenting with moderate fever to pediatric emergency rooms of the Metropolitan Region (Santiago Chile Hum Vaccines 2006 2 129-33 (Pubitemid 44298030)
31. Tarallo L, Tancredi F, Schito G, et al. Active surveillance of Streptococcus pneumoniae bacteremia in Italian children. Vaccine 2006;24:6938-43 (Pubitemid 46131396)
32. Benito-Fernandez J, Raso SM, Pocheville-Gurutzeta I, et al. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. Pediatr Infect Dis J 2007;26:667-71 (Pubitemid 47424633)
33. Alpern ER, Alessandrini EA, McGowan KL, et al. Serotype prevalence of occult pneumococcal bacteremia. Pediatrics 2001;108:E23
34. Rothrock SG, Harper MB, Green SM, et al. Do oral antibiotics prevent meningitis and serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia? A meta-analysis. Pediatrics 1997;99:438-44 (Pubitemid 27176019)
35. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010;16:217-25
36. Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006;32:139-53 (Pubitemid 44221660)
37. Zeretzke CM, McIntosh MS, Kalynych CJ, et al. Reduced use of occult bacteremia blood screens by emergency medicine physicians using immunization registry for children presenting with fever without a source. Pediatr Emerg Care 2012;28:640-5
38. Fonseca W, Hoppu K, Rey LC, et al. Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. Antimicrob Agents Chemother 2003;47:997-1001 (Pubitemid 36254226)
39. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998;42:2375-9 (Pubitemid 28420381)
40. Nudelman Y, Tunkel AR. Bacterial meningitis. Epidemiology, pathogenesis and management updates. Drugs 2009;69:2577-96
41. Brouwer Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microb Rev 2010;23:467-92
42. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360:244-56
43. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998;27:1117-27
44. Chen Z, Wang Y, Zeng A, et al. The clinical diagnostic significance of cerebrospinal fluid D-lactate for bacterial meningitis. Clin Chim Acta 2012;413:1512-15
45. Hameed N, Tunkel AR. Treatment of drug resistant pneumococcal meningitis. Curr Infect Dis Rep 2010;12:274-81
46. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84 (Pubitemid 39458512)
47. Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991;35:2467-72
48. Esposito S, Semino M, Picciolli I, Principi N. Should corticosteroids be used in bacterial meningitis in children? Eur J Paediatr Neurol 2012; Epub ahead of print
49. Rodriguez CA, Atkinson R, Bitar W, et al. Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact. J Infect Dis 2004;190:1481-7 (Pubitemid 39332189)
50. Odio CM, Puig JR, Feris JM, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 1999;18:581-90 (Pubitemid 29350323)
51. Saez-Llorens X, McCoig C, Feris JM, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002;21:14-22 (Pubitemid 34073952)
52. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004;113:1451-65
53. Marchisio P, Bellussi L, Di Mauro G, et al. Acute otitis media: from diagnosis to prevention. Summary of the Italian guideline. Int J Pediatr Otorhinolaryngol 2010;74:1209-16
54. Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993;12:973-5 (Pubitemid 23360865)
55. Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997;176:1253-9
56. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9 (Pubitemid 26098477)
57. Blumer JL. Implications of pharmacokinetics in making choices for the management of acute otitis media. Pediatr Infect Dis J 1998;17:565-70 (Pubitemid 28287637)
58. Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1997;16:710-11 (Pubitemid 27300710)
59. Piglansky L, Leibovitz E, Raiz S, et al. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J 2003;22:405-13
60. Pichichero ME, Casey JR, Hoberman A, Schwartz R. Pathogens causing recurrent and difficult-to-treat acute otitis media, 2003-2006. Clin Pediatr (Phila) 2008;47:901-6
61. Ongkasuwan J, Valdez TA, Hulten KG, et al. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008;122:34-9
62. Xu Q, Pichichero ME, Casey JR, Zeng M. Novel type of Streptococcus pneumoniae causing multidrug-resistant acute otitis media in children. Emerg Infect Dis 2009;15:547-51
63. Gilani Z, Kwong YD, Levine OS, et al. A literature review and survey of childhood pneumonia etiology studies: 2000-2010. Clin Infect Dis 2012;54(Suppl 2):102-8
64. Esposito S, Principi N. Unsolved problems in the approach to pediatric community-acquired pneumonia. Curr Opin Infect Dis 2012;25:286-91
65. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011;66(Suppl 2):1-23
66. Esposito S, Cohen R, Domingo JD, et al. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J 2012;31:e78-85
67. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53:e25-76
68. Esposito S, Marchese A, Tozzi AE, et al. Bacteremic pneumococcal community-acquired pneumonia in children less than 5 years of age in Italy. Pediatr Infect Dis J 2012;31:705-10
69. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369:1179-86 (Pubitemid 46527876)
70. Patrzałek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 2010;29:787-92
71. Yu J, Salamon D, Marcon M, Nahm MH. Pneumococcal serotypes causing pneumonia with pleural effusion in pediatric patients. J Clin Microbiol 2011;49:534-8
72. Picazo J, Ruiz-Contreras J, Hernandez B, et al. Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007-2009) laboratory-based surveillance in Madrid. Vaccine 2011;29:1770-6
73. Chibuk TK, Robinson JL, Hartfield DS. Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with Pneumococcal Conjugate Vaccine (PCV7). Eur J Pediatr 2010;169:1123-8
74. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008;52:24-36
75. Woodnutt G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:35-40 (Pubitemid 29069196)
76. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009;30:210-38
77. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl J Med 1995;333:474-80
78. Tan TQ, Mason EO Jr, Wald ER, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics 2002;110:1-6 (Pubitemid 34742634)
79. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-7 (Pubitemid 36930354)
80. Paganini H, Guinazu JR, Hernandez C, et al. Comparative analysis of outcome and clinical features in children with pleural empyema caused by penicillin-nonsusceptible and penicillin-susceptible Streptococcus pneumoniae. Int J Infect Dis 2001;5:86-8 (Pubitemid 32661024)
81. Kabra SK, Lodha R, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev 2010;3:CD004874
82. Turret GS, Blum S, Fazal BA, et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence. Clin Infect Dis 1999;29:321-7 (Pubitemid 29380194)
83. Dowell SF, Smith T, Leversedge K, Snitzer J. Pneumonia treatment failure associated with highly resistant pneumococci. Clin Infect Dis 1999;29:462-3 (Pubitemid 29380231)
84. Choi E, Lee H. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998;26:1346-54 (Pubitemid 28270164)
85. American Academy of Pediatrics Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Pediatrics 1997;99:289-99
86. Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 2010;32:66-88
87. Davies TA, Flamm RK, Lynch AS. Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. Int J Antimicrob Agents 2012;39:534-8
88. Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 2012;39:240-6
89. File TM Jr, Wilmox MH, Stein GE. Summary of ceftaroline fosemil clinical trial studies and clinical safety. Clin Infect Dis 2012;55(S3):173-80
90. Maselli DJ, Fernandez JF, Whong CY, et al. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist 2012;5:43-51
91. Falco V, Sanchez A, Pahissa A, Rello J. Emerging drugs for pneumococcal pneumonia. Expert Opin Emerg Drugs 2011;16:459-77
92. Cohen R, Levy C, Bingen E, et al. Nasopharyngeal carriage in healthy children before and after 13-valent pneumococcal conjugate vaccine implementation [abstract G-1049]. Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA
93. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29:9127-31
94. Vergison A. Pneumococcal Conjugates: impact of expanded valent vaccines [abstract 439]. Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA
95. Levy C, Varon E, Bingen E, et al. Effect of 7-valent and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in French children under 2 years [abstract G-864]. Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September 2012; San Francisco, CA
96. Principi N, Esposito S. Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. Hum Vaccin 2011;7:905-12